Careers Contact Us

EN

CN

About Gan & Lee

About Gan & Lee

The first company in China to master the technology for the industrial-scale production of recombinant insulin analogs
Committed to delivering high-quality medicines and services to improve lives worldwide

Company Profile:

Delivering high-quality medicines and services to improve lives worldwide

Gan & Lee Pharmaceuticals (603087.SH), founded in 1998, is a global biopharmaceutical company centered on independent innovation. Guided by its mission “Delivering high-quality medicines and services to improve lives worldwide,” the company maintains deep expertise in core endocrine and metabolic therapeutic areas while proactively expanding into frontier fields including oncology, autoimmune diseases. The company strives to become a global innovation leader in endocrine and metabolic therapeutics.

Gan & Lee was the first domestic company to achieve the industrialization of recombinant insulin analogs and has spearheaded transformations within China’s insulin industry. It offers a comprehensive portfolio spanning the full spectrum of long-acting, rapid-acting, and premixed insulin products and secured the largest total contracted volume among all winning bidders in the 2024 National Volume-Based Procurement exclusively for insulin.

Through a steadfast commitment to innovation-driven R&D, Gan & Lee has established multiple advanced technology platforms covering peptides, PROTAC, antibodies, building end-to-end R&D capabilities from original innovation to industrialization. With integrated R&D centers and manufacturing facilities in Beijing and Linyi, Shandong, the company holds over 80 international registration certificates, with its products commercially available in more than 21 countries across Europe, the Asia-Pacific, Latin America, and Africa.

  • 1998

    Founded

  • 5,500+

    Global Workforce

  • 600,000+m²

    Industrial Park Area

  • 603087.SH

    SSE Stock Code

Company Culture

Mission

Mission

Delivering high-quality medicines and services to improve lives worldwide

Vision

Vision

Expanding our impact worldwide in becoming a leading global pharmaceutical company

Core Values

Core Values

Science & Excellence

Principle

Principle

Quality First Innovation Forever

Development History

1998

Company founded, achieving China's "zero-to-one breakthrough" in insulin

  • Founder Dr. Zhongru Gan developed China's first genetically recombinant human insulin (2nd-generation insulin)
  • Established an R&D center and built the world's third-largest insulin production base, laying the foundation for industrialization
2001

Led China into the era of 3rd-generation insulin

  • China's first human insulin analog (3rd-generation insulin)——Prandilin® was successfully developed
2002

Repeatedly filled gaps in the Chinese industry

  • China's first long-acting 3rd-generation insulin——Basalin® was successfully developed
  • China's first premixed human insulin analog, Prandilin® 25, was successfully developed
2005

The first China-produced 3rd-generation insulin was launched, and the internationalization strategy was fully initiated

  • Insulin Glargine Injection——Basalin® was officially launched
  • Achieved overseas commercialization for the first time, opening a new chapter in globalization
2007

A full-line insulin matrix of "long-acting + rapid-acting + premixed" was formed

  • Insulin Lispro Injection——Prandilin® was launched
2014

First overseas subsidiary established

  • US subsidiary established
2015

Dual upgrade of clinical development and supply chain

  • First clinical trial in Europe and the US was initiated
  • The 3rd-generation insulin workshop at the new Beijing plant was completed and put into operation, upgrading supply chain capabilities
2020

Entered the capital market, stepping into a new stage of high-quality development

  • Listed on the A-share main board of the Shanghai Stock Exchange
  • China's first Insulin Aspart Injection——Rapilin® was approved for marketing, further completing the product matrix
  • The world's largest production base——the Linyi, Shandong production base construction was initiated
2021

Won bids in centralized procurement, achieving substantial progress in original research and innovation

  • Six products won bids with high rankings in the national centralized procurement
  • First innovative drug under investigation, GZR18 (GLP-1RA), received approval for Phase I clinical trials in China and the US
2022

Multiple breakthroughs in the innovation pipeline, continuously deepening the layout in the metabolic field

  • Three innovative drugs under investigation, GZR18, GZR4, and GZR101, made significant progress in clinical trials in China and the US
  • First oral hypoglycemic drug, Sitagliptin Phosphate Tablets, was approved for marketing
2024

Market status strengthened, quality system received international recognition

  • Ranked first in the follow-up national centralized procurement for insulin
  • Passed the GMP inspection conducted by the European Medicines Agency
2026

China's insulin products received marketing authorization in the EU for the first time

  • The three core insulin products, insulin glargine, insulin lispro, and insulin aspart, all received approval in the EU

Honors and Qualifications

  • China Patent Gold Award

  • Second Prize of the National Science and Technology Progress Award

  • National Intellectual Property Demonstration Enterprise

  • National Green Factory

  • National Manufacturing Single-Product Champion Enterprise

  • Forbes China Best Employer Award

  • Sustainability Influencer Awards

  • Corporate Governance Award and Golden Information Disclosure Award

Gan & Lee Global

Gan & Lee Pharmaceuticals

Major Domestic Subsidiaries

Major International Subsidiarie

  • Gan & Lee Pharmaceuticals USA Corporation (New Jersey)
  • Gan & Lee Pharmaceuticals Europe GmbH (Germany)
  • Gan & Lee Pharmaceuticals do Brasil Comercio e Importadora de Medicamentos Ltda.